Business
Coya Therapeutics to Present Proof-of-Concept Clinical Data for Low-Dose Interleukin-2 (ld IL-2) for the Treatment of Patients with Alzheimer’s Disease (AD) at the 2023 Alzheimer’s Association International Conference (AAIC)
The academic proof-of-concept open-label study evaluated the biological activity, cytokine and chemokine blood biomarkers, safety, and preliminary efficacy
About this update from Coya Therapeutics, Inc.
[{"type":"text","content":"\n\nThe academic proof-of-concept open-label study evaluated the biological activity, cytokine and chemokine blood biomarkers, safety, and preliminary efficacy of low-dose interleukin-2 (ld IL-2) in 8 patients with mild-to-moderate AD. The study was conducted by Dr. Appel and Dr. Faridar at the Houston Methodist Hospital.\n\n\n\nCoya’s investigational low-dose interleukin-2 (ld IL-2) for subcutaneous administration has been designed to enhance in vivo the anti-inflammatory function of regulatory T cells (Tregs).\n\n\n\nTreg dysfunction has been associated with increased neuroinflammation, which is observed in AD and other neurodegenerative diseases, and may contribute to disease severity and progression.\n\n\n\n HOUSTON--(BUSINESS WIRE)--\nCoya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, today announced the presentation of results from an academic clinical study in patients with Alzheimer’s Disease (AD) with subcutaneous ld IL-2 at the 2023 Alzheimer’s Association International Conference (AAIC) to be held in Amsterdam, Netherlands, from July 16-20, 2023.\n\n\nThe proof-of-concept open-label clinical study is the first-of-its-kind evaluating subcutaneous ld IL-2 immunotherapy for the treatment of AD. Patients in the study received investigational ld IL-2 treatment for 4 consecutive months and were evaluated for safety and tolerability, Treg function, blood biomarkers of inflammation, and clinical functioning as measured by the Clinical Dementia Rating (CDR), the Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog), and the Mini-Mental State Examination (MMSE).\n\n\nAlzheimer’s disease is a progressive neurological condition usually seen in people over the age of 65 in which the death of brain cells causes memory loss and cognitive decline. It is the most common type of dementia, accounting for around 60–80% of cases of dementia in the United States. Alzheimer’s disease affects around 5 million people in the US with estimates suggesting that this number will nearly triple by 2060.\n\n\nThe study was conducted by Stanley Appel, M.D. and Alireza Faridar, M.D. at the Houston Methodist Research Institute (Houston, Texas). Dr. Appel is chair of Coya’s Scientific Advisory Board and is former...